TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below.
If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener:
http://www.thestreet.com/k/qr/flat/stock-screener.html
Upgrades: OMC, WMS
Downgrades: ALSK, ATV, BP, CARB, CMP, CRL, DAN, FRT, SNY, VNO, WU, ZIXI
Initiations: None
Read on to get TheStreet Quant Ratings' detailed report:
The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.
U.S. stock futures trade lower, Donald Trump's national security advisers look at building a 5G network, and France's Sanofi buys Belgian biotech Ablynx.
With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.
The stock market's impressive start to the year is at risk as the government shutdown enters day three. Meanwhile, a series of healthcare deals captivates Wall Street's attention.
U.S. stock futures suggest Wall Street will open lower on Monday, as investors watch for the impact of a federal government shutdown that has extended into its third day.
France's Sanofi could end its long search for a biotech deal after striking an $11.6 billion offer for Massachusetts-based Bioverativ, a maker of hemophilia treatments.
Sanofi has launched two new late-stage clinical studies to determine if an investigational biologic called isatuximab, when used in combination with other commonly used cancer treatments, might be an effective treatment...
Two large real-world analyses compared adults with type 2 diabetes who were switched to Toujeo (insulin glargine injection 300 Units/mL) to those switched to insulin degludec